EC Number   |
Inhibitors |
Structure |
|---|
   2.7.11.30 | (1'R,5'S,6'S)-2-(3',5'-dibromo-1',6'-dihydroxy-4'-oxocyclohex-2'-enyl) acetonitrile |
the small dibromotyrosine derivative purified from Pseudoceratina sp. suppresses TGF-beta responsiveness by inhibiting TGF-beta type I receptor serine/threonine kinase activity. The compound inhibits the TGF-beta-stimulated transcriptional activations of 3TP-Lux and decreases phosphorylated Smad2/3 levels and the nuclear translocation of Smad2/3 increased by TGF-beta. The compound inhibits TGF-beta-induced EMT and wound healing of A-549 cells and is a potential therapeutic agent for fibrotic disease and cancer treatment. The compound has no effects on TGF-beta receptor synthesis but attenuates TGF-beta-induced transcriptional activation in Mv1Lu cells and TGF-beta-induced expression of fibronectin and PAI-1 in A549 and NMuMG cells and TGF-beta-induced cell migration |
   |
| 2.7.11.30 | 1-(1,3-benzodioxol-5-yl)-2-(6-ethylpyridin-2-yl)ethanone |
- |
|
| 2.7.11.30 | 1-(1,3-benzodioxol-5-yl)-2-(6-methylpyridin-2-yl)ethanone |
- |
|
| 2.7.11.30 | 1-(1,3-benzodioxol-5-yl)-2-bromo-2-(6-ethylpyridin-2-yl)ethanone |
- |
|
| 2.7.11.30 | 1-(1,3-benzodioxol-5-yl)-2-bromo-2-(6-methylpyridin-2-yl)ethanone |
- |
|
| 2.7.11.30 | 1-(1,3-benzodioxol-5-yl)-2-bromo-2-pyridin-2-ylethanone |
- |
|
| 2.7.11.30 | 1-(1,3-benzodioxol-5-yl)-2-pyridin-2-ylethanone |
- |
|
| 2.7.11.30 | 2,6-lutidine |
i.e. 2,6-dimethylpyridine |
|
| 2.7.11.30 | 2-(6-ethylpyridin-2-yl)-1-quinoxalin-6-ylethanone |
- |
|
| 2.7.11.30 | 2-(6-methylpyridin-2-yl)-1-quinoxalin-6-ylethanone |
- |
|
